About Cytokinetics (NASDAQ:CYTK)
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.
Industry, Sector and Symbol
Trailing P/E Ratio-3.21010424083953
Forward P/E Ratio-4.02
Sales & Book Value
Annual Sales$13.37 million
Price / Sales33.33
Price / CashN/A
Book Value$2.04 per share
Price / Book4.04
Return on Equity-96.95%
Return on Assets-41.65%
Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions
What is Cytokinetics' stock symbol?
Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."
How were Cytokinetics' earnings last quarter?
Cytokinetics, Inc. (NASDAQ:CYTK) released its quarterly earnings data on Thursday, February, 15th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.04. The biopharmaceutical company earned ($0.02) million during the quarter, compared to analyst estimates of $4.83 million. Cytokinetics had a negative return on equity of 96.95% and a negative net margin of 172.27%. View Cytokinetics' Earnings History.
When will Cytokinetics make its next earnings announcement?
Where is Cytokinetics' stock going? Where will Cytokinetics' stock price be in 2018?
8 brokers have issued 12 month target prices for Cytokinetics' shares. Their predictions range from $10.00 to $24.00. On average, they expect Cytokinetics' stock price to reach $15.75 in the next twelve months. View Analyst Ratings for Cytokinetics.
What are Wall Street analysts saying about Cytokinetics stock?
Here are some recent quotes from research analysts about Cytokinetics stock:
- 1. Cantor Fitzgerald analysts commented, "Robert Califf, M.D. has joined CYTK’s Board of Directors (BoD), adding his expertise in cardiovascular and regulatory domains, we believe." (2/12/2018)
- 2. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (8/17/2017)
- 3. Cowen Inc analysts commented, "CYTK reported a Q2 loss of $29.1MM and ended the quarter with $332MM in cash." (8/4/2017)
Who are some of Cytokinetics' key competitors?
Some companies that are related to Cytokinetics include Collegium Pharmaceutical (COLL), Amphastar Pharmaceuticals (AMPH), Flexion Therapeutics (FLXN), Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), Pharming Group (PHGUF), Geron (GERN), Dova Pharmaceuticals (DOVA), Jounce Therapeutics (JNCE), Alder Biopharmaceuticals (ALDR), ProMetic Life Sciences (PFSCF), Consort Medical (CSRMY), MiMedx Group (MDXG), Anika Therapeutics (ANIK), Menlo Therapeutics (MNLO), La Jolla Pharmaceutical (LJPC), Urogen Pharma (URGN) and CymaBay Therapeutics (CBAY).
Who are Cytokinetics' key executives?
Cytokinetics' management team includes the folowing people:
- Leonard Patrick Gage Ph.D., Independent Chairman of the Board (Age 74)
- Robert I. Blum, President, Chief Executive Officer, Director (Age 53)
- Ching Jaw, Chief Financial Officer, Senior Vice President (Age 54)
- Sharon A. Barbari, Executive Vice President - Finance (Age 62)
- Fady I. Malik M.D. Ph.D., Executive Vice President - Research and Development (Age 52)
- Peter S. Roddy, Senior Vice President, Chief Accounting Officer (Age 57)
- David W. Cragg, Senior Vice President - Human Resources (Age 61)
- Bonnie A. Charpentier Ph.D., Senior Vice President - Regulatory Affairs and Compliance (Age 65)
- Bradley Paul Morgan Ph.D., Senior Vice President - Research and Non-Clinical Development (Age 56)
- Elisabeth Schnieders Ph.D., Senior Vice President - Business Development (Age 50)
Has Cytokinetics been receiving favorable news coverage?
News stories about CYTK stock have been trending somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cytokinetics earned a coverage optimism score of 0.11 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 45.70 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Cytokinetics' major shareholders?
Cytokinetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.44%), BVF Inc. IL (10.62%), Wasatch Advisors Inc. (3.12%), Pinnacle Associates Ltd. (1.63%), Bank of New York Mellon Corp (1.00%) and Geode Capital Management LLC (0.80%). Company insiders that own Cytokinetics stock include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Institutional Ownership Trends for Cytokinetics.
Which major investors are selling Cytokinetics stock?
CYTK stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Pinnacle Associates Ltd., Sphera Funds Management LTD., Schwab Charles Investment Management Inc., TIAA CREF Investment Management LLC, Metropolitan Life Insurance Co. NY and Bank of New York Mellon Corp. Company insiders that have sold Cytokinetics company stock in the last year include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Insider Buying and Selling for Cytokinetics.
Which major investors are buying Cytokinetics stock?
CYTK stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Wasatch Advisors Inc., BlackRock Inc., Tekla Capital Management LLC, Goldman Sachs Group Inc., Deutsche Bank AG, Two Sigma Investments LP and Arizona State Retirement System. View Insider Buying and Selling for Cytokinetics.
How do I buy shares of Cytokinetics?
Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytokinetics' stock price today?
One share of CYTK stock can currently be purchased for approximately $8.25.
How big of a company is Cytokinetics?
Cytokinetics has a market capitalization of $450.97 million and generates $13.37 million in revenue each year. The biopharmaceutical company earns $-127,790,000.00 in net income (profit) each year or ($2.57) on an earnings per share basis. Cytokinetics employs 137 workers across the globe.
How can I contact Cytokinetics?
Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]
MarketBeat Community Rating for Cytokinetics (CYTK)MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cytokinetics (NASDAQ:CYTK) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.88||2.89||2.90||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$15.75||$16.78||$17.90||$22.00|
|Price Target Upside: ||90.91% upside||116.49% upside||146.90% upside||53.85% upside|
Cytokinetics (NASDAQ:CYTK) Consensus Price Target History
Cytokinetics (NASDAQ:CYTK) Analyst Ratings History
(Data available from 3/24/2016 forward)
Cytokinetics (NASDAQ:CYTK) Earnings History and Estimates Chart
Cytokinetics (NASDAQ CYTK) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/15/2018||Q4 2017||($0.71)||($0.75)||$4.83 million||($0.02) million||View||Listen|
|10/26/2017||Q3 2017||($0.64)||($0.60)||$5.35 million||$6.18 million||View||N/A|
|8/2/2017||Q2 2017||($0.57)||($0.60)||$5.28 million||$3.05 million||View||Listen|
|4/27/2017||Q1 2017||($0.11)||($0.62)||$5.08 million||$4.15 million||View||N/A|
|2/16/2017||Q416||($0.39)||$0.16||$14.10 million||$33.14 million||View||Listen|
|10/27/2016||Q3||($0.27)||$0.74||$6.67 million||$59.05 million||View||Listen|
|7/28/2016||Q2||($0.28)||($0.29)||$7.80 million||$5.80 million||View||Listen|
|4/28/2016||Q1||($0.37)||($0.31)||$8.14 million||$8.42 million||View||Listen|
|2/16/2016||Q415||($0.32)||($0.24)||$10.49 million||$9.80 million||View||Listen|
|10/29/2015||Q315||($0.30)||($0.23)||$11.24 million||$7.90 million||View||Listen|
|7/29/2015||Q2||($0.28)||($0.27)||$4.00 million||$6.54 million||View||Listen|
|4/30/2015||Q1||($0.08)||($0.23)||$10.10 million||$4.40 million||View||Listen|
|2/12/2015||Q4||($0.17)||$0.23||$10.80 million||$21.80 million||View||Listen|
|10/30/2014||Q3||($0.27)||($0.16)||$6.50 million||$9.42 million||View||Listen|
|7/30/2014||Q2||($0.32)||($0.23)||$7.01 million||$7.80 million||View||Listen|
|5/6/2014||Q1||($0.34)||($0.27)||$7.69 million||$8.00 million||View||Listen|
|2/6/2014||Q4||($0.08)||$0.21||$19.14 million||$24.30 million||View||Listen|
|10/30/2013||Q3 2013||($0.09)||($0.43)||$15.77 million||$4.47 million||View||N/A|
|7/31/2013||Q2 2013||($0.55)||($0.58)||$4.36 million||$1.01 million||View||N/A|
|4/30/2013||Q1 2013||($0.54)||($0.54)||$0.92 million||$0.82 million||View||N/A|
Cytokinetics (NASDAQ:CYTK) Earnings Estimates
Current Year EPS Consensus Estimate: $-2.05 EPS
Next Year EPS Consensus Estimate: $-2.13 EPS
Dividend History for Cytokinetics (NASDAQ:CYTK)
No dividend announcements for this company have been tracked by MarketBeat.com
Cytokinetics (NASDAQ CYTK) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.20%
Institutional Ownership Percentage: 71.41%
Cytokinetics (NASDAQ CYTK) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/16/2018||Caryn Gordon Mcdowell||Insider||Sell||2,709||$9.00||$24,381.00||15,077|| |
|11/2/2017||Caryn Gordon Mcdowell||Insider||Sell||4,260||$12.94||$55,124.40||17,982|| |
|11/1/2017||Fady Ibraham Malik||EVP||Sell||7,321||$13.39||$98,028.19||47,540|| |
|11/1/2017||Robert I Blum||CEO||Sell||5,000||$13.51||$67,550.00||70,180|| |
|10/6/2017||Caryn Gordon Mcdowell||Insider||Sell||13,181||$15.49||$204,173.69|| |
|10/2/2017||Robert I Blum||CEO||Sell||5,000||$14.59||$72,950.00|| |
|9/6/2017||Caryn Gordon Mcdowell||Insider||Sell||10,131||$14.60||$147,912.60||19,801|| |
|9/1/2017||Robert I Blum||CEO||Sell||5,000||$14.71||$73,550.00||79,785|| |
|8/31/2017||Bradley Paul Morgan||SVP||Sell||118,330||$15.00||$1,774,950.00||63,107|| |
|8/31/2017||Santo J Costa||Director||Sell||5,000||$15.00||$75,000.00||5,000|| |
|8/29/2017||Santo J Costa||Director||Sell||5,000||$14.00||$70,000.00||5,000|| |
|8/8/2017||Caryn Gordon Mcdowell||Insider||Sell||11,348||$12.47||$141,509.56||21,570|| |
|8/1/2017||Robert I Blum||CEO||Sell||5,000||$13.79||$68,950.00||84,785|| |
|7/3/2017||Robert I Blum||CEO||Sell||5,000||$12.14||$60,700.00||88,385|| |
|6/1/2017||Robert I Blum||CEO||Sell||5,000||$13.62||$68,100.00||94,785|| |
|12/29/2016||Fady Ibraham Malik||EVP||Sell||5,633||$12.36||$69,623.88||3,361|| |
|8/31/2015||L Patrick Gage||Director||Buy||1,000||$6.95||$6,950.00||30,000|| |
|8/20/2015||L Patrick Gage||Director||Buy||10,000||$6.55||$65,500.00||30,000|| |
|5/6/2015||L Patrick Gage||Director||Buy||10,000||$5.71||$57,100.00|| |
|3/11/2015||Andrew A Wolff||CMO||Sell||21,875||$7.80||$170,625.00|| |
|12/30/2014||Fady Ibraham Malik||SVP||Sell||21,630||$6.73||$145,569.90|| |
|5/9/2014||L Patrick Gage||Director||Buy||10,850||$4.09||$44,376.50||10,000|| |
|2/25/2014||Eastern Capital Ltd||major shareholder||Buy||500,000||$8.00||$4,000,000.00||2,883,845|| |
Cytokinetics (NASDAQ CYTK) News Headlines
|Cytokinetics (CYTK) Rating Increased to Sell at BidaskClub|
www.americanbankingnews.com - March 24 at 1:11 PM
|Cytokinetics, Inc. (CYTK) Given Consensus Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - March 18 at 1:48 PM
|Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day|
finance.yahoo.com - February 28 at 3:13 PM
|Cytokinetics (CYTK) PT Raised to $18.00|
www.americanbankingnews.com - February 21 at 5:30 PM
|Cytokinetics, Inc. (CYTK) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - February 21 at 2:31 PM
|Cytokinetics (CYTK) Earns Buy Rating from Cowen|
www.americanbankingnews.com - February 20 at 8:26 PM
|Cytokinetics Sees Unusually Large Options Volume (CYTK)|
www.americanbankingnews.com - February 20 at 6:56 AM
|Cytokinetics (CYTK) Announces Earnings Results, Misses Estimates By $0.04 EPS|
www.americanbankingnews.com - February 16 at 11:40 AM
|Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results - GlobeNewswire (press release)|
globenewswire.com - February 16 at 5:10 AM
|Cytokinetics reports 4Q loss|
finance.yahoo.com - February 16 at 5:10 AM
|Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results|
finance.yahoo.com - February 16 at 5:10 AM
|Cytokinetics, Inc. (CYTK) Expected to Post Quarterly Sales of $4.83 Million|
www.americanbankingnews.com - February 16 at 3:46 AM
|Cytokinetics Earnings Outlook - Benzinga|
www.benzinga.com - February 15 at 3:10 PM
|Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference - GlobeNewswire (press release)|
globenewswire.com - February 15 at 5:10 AM
|Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference|
finance.yahoo.com - February 15 at 5:10 AM
| Analysts Expect Cytokinetics, Inc. (CYTK) Will Announce Earnings of -$0.71 Per Share|
www.americanbankingnews.com - February 14 at 5:16 PM
|Cytokinetics Names Robert Califf, M.D., to Board of Directors ... - GlobeNewswire (press release)|
www.globenewswire.com - February 14 at 3:09 PM
|Cytokinetics (CYTK) Names Robert Califf to Board of Directors|
www.streetinsider.com - February 13 at 3:07 PM
|Cytokinetics' (CYTK) Hold Rating Reiterated at Cantor Fitzgerald|
www.americanbankingnews.com - February 12 at 4:18 PM
|Cytokinetics (CYTK) Names Robert Califf to Board of Directors - StreetInsider.com|
www.streetinsider.com - February 12 at 3:07 PM
|Cytokinetics: Multiple Catalysts Could Help With Rebound - Seeking Alpha|
seekingalpha.com - February 7 at 5:15 AM
|Cytokinetics (CYTK) Set to Announce Quarterly Earnings on Wednesday|
www.americanbankingnews.com - February 7 at 2:14 AM
|Head to Head Survey: Loxo Oncology (LOXO) & Cytokinetics (CYTK)|
www.americanbankingnews.com - February 5 at 11:14 PM
|Cytokinetics to Announce Fourth Quarter Results on February 15 ... - GlobeNewswire (press release)|
globenewswire.com - February 3 at 3:06 PM
|Cytokinetics to Announce Fourth Quarter Results on February 15, 2018|
finance.yahoo.com - February 3 at 5:05 AM
|Zacks: Brokerages Expect Cytokinetics, Inc. (CYTK) Will Announce Earnings of -$0.71 Per Share|
www.americanbankingnews.com - January 28 at 5:12 PM
|Cytokinetics, Inc. (CYTK) Receives Consensus Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - January 27 at 2:00 PM
|Cytokinetics (CYTK) Given a $20.00 Price Target by HC Wainwright Analysts|
www.americanbankingnews.com - January 20 at 7:38 PM
|Cytokinetics (CYTK) PT Raised to $20 at HC Wainwright; 'The Year of CK-107' - StreetInsider.com|
www.streetinsider.com - January 20 at 3:16 PM
|Cytokinetics, Inc. (CYTK) Insider Caryn Gordon Mcdowell Sells 2,709 Shares|
www.americanbankingnews.com - January 18 at 9:58 PM
|Cantor Fitzgerald Reaffirms "Hold" Rating for Cytokinetics (CYTK)|
www.americanbankingnews.com - January 18 at 1:50 PM
|Zacks: Brokerages Anticipate Cytokinetics, Inc. (CYTK) Will Post Quarterly Sales of $4.83 Million|
www.americanbankingnews.com - January 13 at 5:00 AM
|Zacks: Brokerages Anticipate Cytokinetics, Inc. (CYTK) to Announce -$0.71 EPS|
www.americanbankingnews.com - January 11 at 7:32 PM
|BRIEF-Cytokinetics Announces Progress Against Vision 2020|
www.reuters.com - January 3 at 8:50 AM
|Cytokinetics Announces Progress Against Vision 2020|
finance.yahoo.com - January 3 at 8:50 AM
|$4.83 Million in Sales Expected for Cytokinetics, Inc. (CYTK) This Quarter|
www.americanbankingnews.com - December 28 at 8:32 PM
|Cytokinetics, Inc. (CYTK) Expected to Post Earnings of -$0.71 Per Share|
www.americanbankingnews.com - December 26 at 7:20 AM
|Contrasting Cytokinetics (CYTK) and Its Peers|
www.americanbankingnews.com - December 12 at 7:34 PM
|Cytokinetics further discusses tirasemtiv results; down 2.5% - Seeking Alpha|
seekingalpha.com - December 12 at 5:36 PM
|5 Stocks To Watch For December 11, 2017 - Benzinga|
www.benzinga.com - December 11 at 5:22 PM
|Cytokinetics (CYTK) & The Competition Financial Survey|
www.americanbankingnews.com - December 8 at 5:14 PM
|Cytokinetics Announces Presentation of Results From VITALITY-ALS at 28th International Symposium on ALS/MND|
finance.yahoo.com - December 8 at 5:04 PM
|Cytokinetics, Inc. (CYTK) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - December 8 at 3:52 PM
|-$0.71 Earnings Per Share Expected for Cytokinetics, Inc. (CYTK) This Quarter|
www.americanbankingnews.com - December 8 at 3:30 PM
|Contrasting Cytokinetics (CYTK) & The Competition|
www.americanbankingnews.com - December 7 at 9:24 AM
|Cytokinetics (CYTK) Says New Publication Shows Respiratory Decline Correlated With Disease Progression in People ... - StreetInsider.com|
www.streetinsider.com - December 1 at 5:01 PM
|Cytokinetics Announces Results of VITALITY-ALS to be Presented at the International Symposium on ALS/MND|
finance.yahoo.com - December 1 at 5:01 PM
|New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability and Amplification of Skeletal Muscle Response to Nerve Activation|
finance.yahoo.com - November 30 at 5:07 PM
|Cytokinetics (CYTK) Announces New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability ... - StreetInsider.com|
www.streetinsider.com - November 30 at 10:09 AM
|Needham & Company LLC Downgrades Cytokinetics (CYTK) to Buy|
www.americanbankingnews.com - November 29 at 8:44 AM
Cytokinetics (NASDAQ:CYTK) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cytokinetics (NASDAQ:CYTK) Income Statement, Balance Sheet and Cash Flow Statement
Cytokinetics (NASDAQ CYTK) Stock Chart for Saturday, March, 24, 2018